SAB Biotherapeutics's market cap is currently ―. The company's EPS TTM is $-7.654; its P/E ratio is -0.60; SAB Biotherapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.96. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 1.27M	$ 85.52K	$ 581.10K	$ 0.00	$ 0.00
Gross Profit	$ 1.27M	$ 85.52K	$ 581.10K	-	-
EBIT	$ -5.03M	$ -6.81M	$ -7.32M	$ -7.76M	$ -7.01M
EBITDA	-	$ -5.91M	$ -6.40M	$ -6.84M	$ -6.10M
Net Income Common Stockholders	$ -5.10M	$ -6.88M	$ 8.61M	$ -7.87M	$ -7.08M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 2.43M	$ 7.77M	$ 13.06M	$ 15.05M	$ 8.33M
Total Assets	$ 28.34M	$ 35.44M	$ 42.67M	$ 50.90M	$ 52.51M
Total Debt	$ 4.65M	$ 4.90M	$ 5.46M	$ 5.93M	$ 5.80M
Net Debt	$ 2.23M	$ -2.87M	$ -7.60M	$ -9.12M	$ -2.53M
Total Liabilities	$ 13.08M	$ 15.73M	$ 18.27M	$ 19.85M	$ 21.88M
Stockholders Equity	$ 15.26M	$ 19.72M	$ 24.40M	$ 31.06M	$ 30.62M
Cash Flow	-
Free Cash Flow	-	$ -4.92M	$ -1.63M	$ 98.97K	$ -8.25M
Operating Cash Flow	$ -5.17M	$ -4.90M	$ -1.61M	$ 216.72K	$ -8.17M
Investing Cash Flow	$ -40.86K	$ -22.68K	$ -21.30K	$ -117.75K	$ -78.50K
Financing Cash Flow	$ -140.31K	$ -363.79K	$ -359.79K	$ 6.62M	$ -32.17K

Currency in USD

SAB Biotherapeutics Earnings and Revenue History

Income Statement >

SAB Biotherapeutics Debt to Assets

Balance Sheet >

SAB Biotherapeutics Cash Flow

Cash Flow >

SAB Biotherapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing